Yourgene Health PLC DPYD screening recommended in Belgium
January 13 2021 - 1:00AM
RNS Non-Regulatory
TIDMYGEN
Yourgene Health PLC
13 January 2021
Yourgene Health plc
("Yourgene" or the "Group" or the "Company")
DPYD screening recommended in Belgium
Manchester, UK - 13 January 2021: Yourgene (AIM: YGEN), the
international molecular diagnostics group, welcomes the research
article published on 11 January 2021, in Acta Clinica Belgica,
titled: ' Joint Belgian recommendation on screening for
DPD-deficiency in patients treated with 5-FU, capecitabine (and
tegafur).'
The research article endorses screening for Dihydropyrimidine
Dehydrogenase (DPD) deficiency which can cause severe and sometimes
lethal side effects in patients being treated with chemotherapeutic
drug 5-Fluorouracil (5-FU), commonly used in the treatment of
colon, oesophageal, stomach, pancreatic, breast and cervical
cancers.
Yourgene already has an existing strong customer base and
supplies its Elucigene DPYD test, which identifies cancer patients
with DPD deficiency, directly into Belgium. The Elucigene DPYD
assay is being used by one of the contributing institutes, the
University Hospital St Luc/ UCLouvain, Woluwe, Belgium, where the
lead author of the research publication is based. This follows on
from the positive news that DPYD screening has been recommended in
Germany, Wales and most recently by NHS England. The screening
enables clinicians and their patients to avoid the risk of
increased toxicity from a commonly-used chemotherapy treatment, and
the use of lower dose or alternate treatment where indicated. With
the clinical value of DPYD screening being more widely recognised,
the opportunity for significant market growth for Yourgene is
increasing.
Lyn Rees, CEO of Yourgene, commented: "The clinical value of
DPYD screening is being increasingly recognised globally through
such recommendations and we are in a strong position with our
Elucigene DPYD test to support and expand into these markets . We
are proud to already have an existing customer base in Belgium
which we will continue to supply. We are pleased to see the wider
recognition of the benefits of DPYD testing and the associated
growth in market potential for our Elucigene DPYD test."
Yourgene Health plc Tel: +44 (0)161 669 8122
Lyn Rees, Chief Executive Officer investors@yourgene-health.com
Barry Hextall, Chief Financial Officer
Joanne Cross, Director of Marketing
N+1 Singer (Joint Corporate Broker) Tel: +44 (0)20 7496 3000
Aubrey Powell / Tom Salvesen / George
Tzimas
Stifel Nicolaus Europe Limited (Joint Tel: +44 (0)20 7710 7600
Corporate Broker)
Nicholas Moore / Matthew Blawat / Ben
Maddison
Walbrook PR Ltd (Media and Investor Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com
Relations)
Paul McManus / Lianne Cawthorne Mob: 07980 541 893 / Mob: 07584
391 303
About Yourgene Health
Yourgene Health is an international molecular diagnostics group
which develops and commercialises genetic products and services.
The group works in partnership with global leaders in DNA
technology to advance diagnostic science.
Yourgene primarily develops, manufactures, and commercialises
simple and accurate molecular diagnostic solutions, for
reproductive health, precision medicine and now infectious
diseases. The Group's flagship products include non-invasive
prenatal tests (NIPT) for Down's Syndrome and other genetic
disorders, Cystic Fibrosis screening tests, invasive rapid
aneuploidy tests, and a recent extension into the oncology space
with DPYD genotyping.
The launch of Yourgene Genomic Services has enabled Yourgene to
offer a global laboratory service network equipped to be a full
life-cycle partner for clinical, research and pharmaceutical
organisations to support partners at the preclinical, clinical, and
post-market stages to develop, manufacture, obtain regulatory
approval and commercialise new products and services. In addition,
Yourgene Genomic Services offers an NIPT and high throughput COVID
testing service.
In August 2020, Yourgene acquired Coastal Genomics, Inc., a
sample preparation technology company based in Vancouver, Canada,
enabling the Company to extend its offering and IP portfolio in the
DNA sample preparation sector. The acquisition increased Yourgene's
geographical penetration into the US and Canada, supplementing
existing coverage in the UK, Europe, MEA and Asia.
Yourgene Health is headquartered in Manchester, UK with offices
in Taipei, Singapore, the US and Canada, and is listed on the
London Stock Exchange's AIM market under the ticker "YGEN". For
more information visit www.yourgene-health.com and follow us on
twitter @Yourgene_Health.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRABIGDBGSBDGBD
(END) Dow Jones Newswires
January 13, 2021 02:00 ET (07:00 GMT)
Yourgene Health (LSE:YGEN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Yourgene Health (LSE:YGEN)
Historical Stock Chart
From Apr 2023 to Apr 2024